PDF(Pubmed)
Abstract：
UNASSIGNED: To explore the effects of budesonide combined with Bifidobacteria and Lactobacilli on the lung function and intestinal microbiota of patients with chronic obstructive pulmonary disease (COPD).
UNASSIGNED: Clinical data of 124 COPD patients admitted to Fengcheng Hospital, Fengxian District, Shanghai from February 2021 to February 2023 were retrospectively analyzed. Patients either received budesonide treatment alone (n=59, control group) or budesonide combined with Bifidobacteria and Lactobacilli (n=65, observation group). Levels of lung function indicators, symptom relief time, gut microbiota levels, and quality of life were compared between the two groups before and after the treatment.
UNASSIGNED: After two weeks of treatment, the improvement of lung function in the observation group was better than that in the control group (P<0.05). Compared to budesonide treatment alone, combined budesonide, Bifidobacteria, and Lactobacilli treatment were associated with shorter symptom relief time (P<0.05), and with more significant improvement of intestinal microbiota level (P<0.05) and the quality of life (P<0.05).
UNASSIGNED: Budesonide combined with Bifidobacteria and Lactobacilli can effectively alleviate clinical symptoms, regulate intestinal microbiota, improve lung function and the quality of life of COPD patients.
UNASSIGNED: Clinical data of 124 COPD patients admitted to Fengcheng Hospital, Fengxian District, Shanghai from February 2021 to February 2023 were retrospectively analyzed. Patients either received budesonide treatment alone (n=59, control group) or budesonide combined with Bifidobacteria and Lactobacilli (n=65, observation group). Levels of lung function indicators, symptom relief time, gut microbiota levels, and quality of life were compared between the two groups before and after the treatment.
UNASSIGNED: After two weeks of treatment, the improvement of lung function in the observation group was better than that in the control group (P<0.05). Compared to budesonide treatment alone, combined budesonide, Bifidobacteria, and Lactobacilli treatment were associated with shorter symptom relief time (P<0.05), and with more significant improvement of intestinal microbiota level (P<0.05) and the quality of life (P<0.05).
UNASSIGNED: Budesonide combined with Bifidobacteria and Lactobacilli can effectively alleviate clinical symptoms, regulate intestinal microbiota, improve lung function and the quality of life of COPD patients.
摘要：
■探讨布地奈德联合双歧杆菌和乳杆菌对慢性阻塞性肺疾病（COPD）患者肺功能和肠道菌群的影响。
■丰城市医院收治的124例COPD患者的临床资料,奉贤区,上海从2021年2月到2023年2月进行回顾性分析。患者接受布地奈德单独治疗（n=59，对照组）或布地奈德联合双歧杆菌和乳杆菌治疗（n=65，观察组）。肺功能指标水平，症状缓解时间,肠道微生物群水平，比较两组患者治疗前后的生活质量。
■治疗两周后，观察组肺功能改善情况优于对照组(P<0.05)。与布地奈德单独治疗相比，联合布地奈德，双歧杆菌,乳杆菌治疗症状缓解时间较短(P<0.05),改善肠道菌群水平(P<0.05),提高生活质量(P<0.05)。
■布地奈德联合双歧杆菌和乳杆菌能有效缓解临床症状，调节肠道微生物群，改善COPD患者的肺功能和生活质量。
■丰城市医院收治的124例COPD患者的临床资料,奉贤区,上海从2021年2月到2023年2月进行回顾性分析。患者接受布地奈德单独治疗（n=59，对照组）或布地奈德联合双歧杆菌和乳杆菌治疗（n=65，观察组）。肺功能指标水平，症状缓解时间,肠道微生物群水平，比较两组患者治疗前后的生活质量。
■治疗两周后，观察组肺功能改善情况优于对照组(P<0.05)。与布地奈德单独治疗相比，联合布地奈德，双歧杆菌,乳杆菌治疗症状缓解时间较短(P<0.05),改善肠道菌群水平(P<0.05),提高生活质量(P<0.05)。
■布地奈德联合双歧杆菌和乳杆菌能有效缓解临床症状，调节肠道微生物群，改善COPD患者的肺功能和生活质量。
